Format

Send to

Choose Destination
J Dermatolog Treat. 2020 May;31(3):222-226. doi: 10.1080/09546634.2019.1597245. Epub 2019 Apr 2.

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

Author information

1
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
2
Department of Dermatology, Hospital del Mar- Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
3
Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
4
Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Spain.
5
Department of Dermatology, Hospital de Sant Joan Despi Moises Broggi, Sant Joan Despí, Spain.
6
Department of Dermatology, Hospital Clínic, Universitat de Barcelona (UB), Barcelona, Spain.
7
Department of Dermatology, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Abstract

Background: Scant information from clinical practice is available on the effectiveness and safety of ustekinumab (UST) 90 mg in patients with psoriasis weighing 100 kg or less.Objectives: To assess the effectiveness and safety at weeks 16 and 24 of UST 90 mg in patients with psoriasis weighing ≤100 kg, and to study the impact on clinical outcomes of body mass index (BMI) and prior exposure to UST 45 mg.Methods: A retrospective, observational, and multicenter study of 74 adult patients who were treated with UST 90 mg at least 24 weeks.Results: Mean (standard deviation [SD]) score on psoriasis area and severity index (PASI) was 7.9 (4.8) at baseline, 3.3 (3.5) at week 16, and 2.2 (2.4) at week 24, when 69.7% of the patients had a PASI under 3. Overweight and obese patients achieved a mean PASI of 2.2 by week 24 (p= .995). In patients who had previously been treated with UST 45 mg (52/74) with insufficient response, mean (SD) absolute PASI score was 2.7 (2.6) at week 24. No serious adverse events were reported.Conclusions: In patients who weigh 100 kg or less but are overweight or obese and do not present an adequate response with UST 45 mg, increasing the dose to UST 90 mg could be an alternative option.

KEYWORDS:

Psoriasis; clinical practice; ustekinumab

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center